

AMENDMENTS TO THE CLAIMS

In the Claims:

1-112. Cancel

113. (Currently Amended) A method for eliciting or enhancing an immune response to HER-2/neu protein, the method comprising the step of administering to a warm-blooded animal a composition comprising an isolated protein comprising a HER-2/neu fusion protein in an amount effective to elicit or enhance the immune response, wherein the HER-2/neu fusion protein comprises an amino acid sequence of consisting of a HER-2/neu extracellular domain fused to a HER-2/neu phosphorylation domain, wherein the HER-2/neu fusion protein comprises at least 90% identity to SEQ ID NO:6, and wherein the HER-2/neu fusion protein is capable of producing an immune response in a warm-blooded animal.
114. (Previously presented) The method of claim 113, wherein the composition is administered in the form of a vaccine.
115. (Canceled)
116. (Previously presented) A method for eliciting or enhancing an immune response to HER-2/neu protein, the method comprising the step of administering to a warm-blooded animal a composition comprising an isolated protein comprising a HER-2/neu fusion protein in an amount effective to elicit or enhance the immune response, wherein the HER-2/neu fusion protein consisting of a HER-2/neu extracellular domain fused to a HER-2/neu phosphorylation domain, wherein the HER-2/neu fusion protein comprises an amino acid sequence of SEQ ID NO:7, and wherein the HER-2/neu fusion protein is capable of producing an immune response in a warm-blooded animal.
117. (Previously presented) The method of claim 113, wherein the fusion protein is lipidated.
118. (Previously presented) The method of claim 113, wherein the composition comprises a physiologically acceptable carrier or diluent.
119. (Previously presented) The method of claim 118, wherein the composition comprises an oil-in-water emulsion.
120. (Previously presented) The method of claim 119, wherein the composition comprises tocopherol.
121. (Previously presented) The method of claim 113, wherein the composition comprises an immunostimulatory substance.

122. (Previously presented) The method of claim 121, wherein the composition comprises an immunostimulatory substance comprising 3D-MPL, QS21, or a combination of 3D-MPL and QS21.
123. (Previously presented) The method of claim 121, wherein the composition comprises an immunostimulatory substance comprising 3D-MPL and QS21 in an oil-in-water emulsion.
124. (Previously presented) The method of claim 123, wherein the composition comprises tocopherol.
125. (Previously presented) The method of claim 113, wherein the composition comprises a CpG-containing oligonucleotide.
- 126-144. (Canceled)
145. (New) The method of claim 116, wherein the composition is administered in the form of a vaccine.
146. (New) The method of claim 116, wherein the fusion protein is lipidated.
147. (New) The method of claim 116, wherein the composition comprises a physiologically acceptable carrier or diluent.
148. (New) The method of claim 147, wherein the composition comprises an oil-in-water emulsion.
149. (New) The method of claim 148, wherein the composition comprises tocopherol.
150. (New) The method of claim 116, wherein the composition comprises an immunostimulatory substance.
151. (New) The method of claim 150, wherein the composition comprises an immunostimulatory substance comprising 3D-MPL, QS21, or a combination of 3D-MPL and QS21.
152. (New) The method of claim 150, wherein the composition comprises an immunostimulatory substance comprising 3D-MPL and QS21 in an oil-in-water emulsion.
153. (New) The method of claim 152, wherein the composition comprises tocopherol.
154. (New) The method of claim 116, wherein the composition comprises a CpG-containing oligonucleotide.